Gandara, David R.
Paul, Sarah M.
Kowanetz, Marcin
Schleifman, Erica
Zou, Wei
Li, Yan
Rittmeyer, Achim
Fehrenbacher, Louis
Otto, Geoff
Malboeuf, Christine
Lieber, Daniel S.
Lipson, Doron
Silterra, Jacob
Amler, Lukas
Riehl, Todd
Cummings, Craig A.
Hegde, Priti S.
Sandler, Alan
Ballinger, Marcus
Fabrizio, David
Mok, Tony
Shames, David S.
Article History
Received: 13 April 2018
Accepted: 22 June 2018
First Online: 6 August 2018
Competing interests
: The authors declare the following competing interests: D.R.G. has received a clinical trial grant and consultant fees from Genentech. Y.L., L.A., T.R., A.S. and M.B. are Genentech employees and holders of Roche stock. M.K., E.S., D.S.S., S.M.P., Y.L. and C.A.C. are Genentech employees and holders of Roche stock and have a patent pending for therapeutic and diagnostic methods for cancer. W.Z. is a Genentech employee and has received research funding from Roche. A.R. has received grants from AstraZeneca, Roche/Genentech, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly and Pfizer. L.F. declares no competing interests. D.F. is a Foundation Medicine employee and stockholder and has a patent pending for therapeutic and diagnostic methods for cancer. G.O., C.M., D.S.L., D.L. and J.S. are Foundation Medicine employees and stockholders. P.S.H. is a Genentech employee. T.M. has received grants/research support from AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, SFJ Pharmaceuticals, Roche, Merck Sharp & Dohme, Clovis Oncology, Bristol-Myers Squibb, Eisai and Taiho; speaker’s fees from AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Taiho and Ariad/Takeda; honoraria/honorarium from AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck Serono, Merck Sharp & Dohme, Novartis, SFJ Pharmaceuticals, ACEA Biosciences, Vertex Pharmaceuticals, Bristol-Myers Squibb, OncoGenex Pharmaceuticals, Celgene and Ignyta; is a major stockholder in Sanomics and Cirina; participated in advisory boards for AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Clovis Oncology, Merck Serono, Merck Sharp & Dohme, Novartis, SFJ Pharmaceuticals, ACEA Biosciences, Vertex Pharmaceuticals, Bristol-Myers Squibb, geneDecode, OncoGenex Technologies, Celgene, Ignyta and Cirina; and is on the board of directors for the International Association for the Study of Lung Cancer (IASLC), the Chinese Lung Cancer Research Foundation, the Chinese Society of Clinical Oncology (CSCO) and the Hong Kong Cancer Therapy Society (HKCTS).